Hepatitis B Virus Compositions and Methods of Use
AssigneeFox Chase Cancer Center
InventorsNing Chai, John M. Taylor
Life of this patent
Estimating the term…
Abstract
A polypeptide comprising a preS1 region of hepatitis B virus (HBV), or a fragment thereof, and/or the preS2 region of HBV or a fragment thereof, and methods of use to inhibit virus infection are disclosed. A lentivirus comprising hepatitis B virus (HBV) envelope proteins, or a fragment thereof, and/or the L envelope protein of HBV and/or the M envelope protein of HBV or a fragment thereof, and/or the S envelope protein of HBV or a fragment thereof, and methods of use of this lentivirus HBV pseudovirus as a gene therapy to target hepatocytes for the administration of therapeutic agents are also disclosed.
Claims52
A secreted recombinant polypeptide comprising at least 30 contiguous amino acids of the sequence of preS1 region of HBV, wherein the polypeptide is capable of inhibiting virus infection of hepatocytes, further wherein the polypeptide does not contain amino acids of the sequence of the S region of HBV.
A method of in vivo inhibition of hepatocyte infection, the method comprising administering an effect amount of a nucleic acid sequence encoding a polypeptide comprising at least 30 contiguous amino acids of the sequence of preS1 region of HBV, wherein the polypeptide is capable of inhibiting virus infection of hepatocytes to an animal in need thereof, further wherein the polypeptide does not contain nucleic acid sequences encoding the S region of HBV.
An isolated polynucleotide encoding a polypeptide comprising at least 30 contiguous amino acids of the sequence of preS1 region of HBV, wherein the polypeptide is capable of inhibiting virus infection of hepatocytes, further wherein the polypeptide does not contain amino acids of the sequence of the S region of HBV.
A method of in vivo inhibition of hepatocyte infection, the method comprising administering an effect amount of a secreted polypeptide comprising at least 30 contiguous amino acids of the sequence of preS1 region of HBV, wherein the polypeptide is capable of inhibiting virus infection of hepatocytes to an animal in need thereof, further wherein the polypeptide does not contain amino acids of the sequence of S region of HBV.
A composition comprising a lentiviral pseudovirus capable of infecting hapatocytes.
A method of producing a lentiviral pseudovirus expressing a Hepatitis B surface protein, the method comprising transfecting a host cell with a first plasmid comprising a modified HIV genome;
- and a second plasmid comprising a HBV gene encoding one or more HBV surface proteins;
- and recovering recombinant virus.
A method for reducing expression of a target gene in a hepatocyte, the method comprising introducing into the hepatocyte a lentiviral vector encoding an inhibitor of gene expression for a gene associated with liver disease, wherein the inhibitor causes a detectable decrease in expression of the gene associated with liver disease.
A method of expressing a target gene in a hepatocyte, the method comprising introducing into the hepatocyte a lentiviral vector encoding a nucleotide sequence specific for a gene associated with liver disease.
A recombinant subviral particle (SVP) comprising an HBV viral envelope protein, wherein said SVP is capable of inhibiting virus infection of hepatocytes.
A method of inhibiting hepatocyte infection, the method comprising contacting a hepatocyte with a recombinant subviral particle (SVP), wherein the SVP comprises an HBV viral envelope protein.
Dependencies are inferred from the claim text.